...
首页> 外文期刊>Polish Archives of Internal Medicine >Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease
【24h】

Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease

机译:慢性肾脏病患者血清κ/λ轻链异常的发生率及临床意义

获取原文
           

摘要

INTRODUCTION A range of malignant diseases (both solid organ tumors and hematogenous malignancies) may manifest as proteinuriaephrotic syndrome. Multiple myeloma (MM) typically involves the kidneys and proteinuria, and chronic kidney disease (CKD) may also be the first manifestation of MM. OBJECTIVES The aim of the study was to evaluate the prevalence and clinical significance of abnormal serum free kappa/lambda light chain ratio in patients referred to a renal center for a diagnostic workup for proteinuria or CKD of an unknown origin (or both). PATIENTS AND METHODS Free light chain tests were performed in 92 consecutive patients (mean age, 63 ±13.9 years; women, 38%; men, 62%) using FreeLite kits. In addition, serum creatinine, calcium, and albumin levels as well as estimated glomerular filtration rate (eGFR) were measured and blood count and proteinuria were assessed. In 39 patients, kidney biopsy was also performed. Nephrotic syndrome was found in 38% of the patients; nonnephrotic proteinuria, in 39.1%; and isolated reduction of eGFR (without proteinuria), in 22.9%. RESULTS MM was confirmed in 5 patients (5.43%; all patients had a highly abnormal kappa/lambda ratio). After the exclusion of the subjects with MM, the abnormal kappa/lambda ratio was found in 37 patients (42.5%); MM was excluded in all patients after careful hematological evaluation, including bone marrow biopsy in 12 cases. The percentage of the abnormal kappa/lambda ratio was high regardless of the proteinuria level, eGFR, or the type of glomerulopathy diagnosed by kidney biopsy. The kappa/ lambda ratio did not correlate with age, proteinuria, or eGFR. CONCLUSIONS Our results suggest that an abnormal kappa/lambda ratio (in most cases higher than normal) is a common and, most likely, nonspecific finding in patients with proteinuria or CKD of an unknown origin (or both).
机译:引言一系列恶性疾病(实体器官肿瘤和血源性恶性肿瘤)都可能表现为蛋白尿/肾病综合征。多发性骨髓瘤(MM)通常累及肾脏和蛋白尿,而慢性肾脏疾病(CKD)也可能是MM的首发表现。目的本研究的目的是评估转诊至肾脏中心以进行蛋白尿或CKD未知来源诊断(或两者)的患者的血清游离κ/λ轻链比例异常的患病率及其临床意义。患者和方法使用FreeLite试剂盒对92例连续患者(平均年龄63±13.9岁;女性38%;男性62%)进行了自由轻链检测。此外,还测量了血清肌酐,钙和白蛋白水平以及估计的肾小球滤过率(eGFR),并评估了血球计数和蛋白尿。在39例患者中,还进行了肾脏活检。在38%的患者中发现了肾病综合征。非肾病性蛋白尿,占39.1%;且eGFR(无蛋白尿)的减少量减少了22.9%。结果5例患者中确诊MM(5.43%;所有患者的kappa / lambda比值均异常高)。排除MM患者后,发现37例患者(42.5%)的kappa / lambda比值异常。经过仔细的血液学评估,所有患者均不包括MM,其中包括12例骨髓活检。无论蛋白尿水平,eGFR或通过肾活检诊断出的肾小球病类型如何,异常κ/ lambda比值的百分比都很高。 κ/λ比与年龄,蛋白尿或eGFR不相关。结论我们的研究结果表明,κ/λ比值异常(在大多数情况下高于正常值)是蛋白尿或CKD来源不明(或两者都有)的患者的常见且最有可能是非特异性的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号